Welcome to our dedicated page for Imunon SEC filings (Ticker: IMNN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Imunon, Inc. filings document a Nasdaq-listed clinical-stage biotechnology issuer with common stock trading under IMNN and a business centered on non-viral DNA-mediated immunotherapy. The company's 8-K reports include financial results, business updates, clinical-program disclosures for IMNN-001 and the OVATION studies, and corporate events affecting executive roles and compensation arrangements.
Proxy and registration-related filings describe annual meeting matters, board and executive compensation governance, common-stock capital structure, and at-the-market equity offering arrangements. The filing record also includes Nasdaq listing-compliance disclosures and other public-company status reports tied to Imunon's financing, governance, and clinical-development operations.
Imunon, Inc. reported Q3 2025 results and operational updates. The company posted a net loss of $3.43 million for the quarter and $10.27 million for the nine months ended September 30, 2025. Operating expenses fell to $3.48 million in Q3 (from $4.96 million a year ago) and to $10.39 million for the nine-month period (from $14.99 million), driven by lower research and development spending.
Cash and cash equivalents were $5.25 million as of September 30, 2025. Year to date, Imunon used $10.24 million in operating cash flows and raised $9.89 million via equity financings and warrant exercises. Management disclosed substantial doubt about the company’s ability to continue as a going concern. As of November 10, 2025, shares outstanding were 3,070,354.
The company effected a 15‑for‑1 reverse stock split on July 25, 2025, increased authorized common shares to 350,000,000 on July 11, and issued a 15% stock dividend on August 21. Clinically, positive Phase 2 OVATION 2 data support IMNN‑001 in advanced ovarian cancer, and the Phase 3 OVATION 3 trial began enrolling in July 2025 with four sites open as of quarter end.
Imunon, Inc. furnished an 8‑K stating it issued a press release reporting financial results for the quarter ended September 30, 2025. The release is attached as Exhibit 99.1 and, consistent with Item 2.02, the information is furnished and not deemed filed under the Exchange Act or Securities Act.
The company also referenced a conference call scheduled for November 13, 2025, announced on November 6, 2025, with a live webcast available at http://www.imunon.com.
Imunon, Inc. (IMNN) reporting person Stacy Lindborg, President & CEO and director, had 1,667 restricted shares vest on September 6, 2025, resulting in an acquisition of 1,667 common shares at $0 per share. After the vesting, Ms. Lindborg beneficially owned 3,584 shares directly and 234 shares indirectly through a 401(k) plan. The filing notes corporate equity adjustments: a 1-for-15 reverse stock split effective July 25, 2025, and a 15% stock dividend paid August 21, 2025, which adjusted previously reported share amounts. The Form 4 was signed by an attorney-in-fact on September 9, 2025.
Imunon, Inc. reports that it has received written notice from a Nasdaq Hearings Panel that the company has regained compliance with the $1.00 minimum closing bid price requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2).
This confirms that Imunon’s common stock, trading under the symbol IMNN, currently meets this key Nasdaq standard and removes the immediate listing risk tied specifically to its share price, as long as the company continues to satisfy applicable Nasdaq rules.
Imunon, Inc. received a Schedule 13G/A reporting that three related reporting persons — Ayrton Capital LLC, Alto Opportunity Master Fund, SPC (Segregated Master Portfolio B) and individual Waqas Khatri — each beneficially own 2,000 shares of the issuer's common stock that are issuable on the exercise of certain warrants and conversion of certain convertible notes. The filing states these holdings represent 0.01% each based on 17,541,732 shares outstanding cited in the issuer's registration statement prior to a July 2025 reverse stock split.
The filing notes the warrants are subject to a 9.99% beneficial ownership blocker and includes a certification that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control.
Reporting persons Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC disclose beneficial ownership in Imunon, Inc. The filing shows each may be deemed to beneficially own 1,067,196 shares of common stock, representing 4.99% of the class. That figure is calculated using the issuer's reported outstanding shares of 20,319,511 plus 1,067,196 shares issuable upon exercise of an Intracoastal warrant.
The report states sole voting and dispositive power are 0 and shared voting and dispositive power are 1,067,196. It also discloses an additional 1,155,028 warrant shares are excluded because the warrant is not currently exercisable pending stockholder approval and includes a blocker limiting exercise above 4.99%. Without that blocker and if currently exercisable, the filing notes each reporting person could be deemed to own 2,222,224 shares.
Imunon, Inc. (IMNN) Form 4: Director Donald P. Braun reported two transactions dated 08/04/2025 following the company’s 1-for-15 reverse split completed 07/25/2025.
- Equity grant in lieu of cash fees: 2,040 common shares acquired at the split-adjusted closing price of $9.20, increasing Braun’s direct holdings to 3,747 shares.
- New stock option: right to purchase 250 shares at an exercise price of $9.20; 50% vests immediately, 25% after one year, and the remaining 25% after two years, expiring 08/04/2035.
Post-transaction, Braun also holds 250 options in addition to the common shares. The share acquisition represents payment of board fees in stock rather than cash, signalling alignment with shareholder interests, though the dollar value (<≈ $18.8 k) is modest relative to market capitalization. No sales were disclosed.